Therefore, we performed the data analysis from this prospective cohort study in Taiwan to compare the risks of cardiovascular diseases, liver cirrhosis, liver-related mortality, and cardiovascular mortality between GLP-1 RA use and no-use in patients with T2D (excluding those with viral hepatitis or alcohol-related disorders). The gene discussed is GCG; the disease is viral hepatitis.